Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NT 219

Next Previous
Drug Profile

NT 219

Alternative Names: NT-219

Latest Information Update: 03 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer Purple Biotech; TyrNovo
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Insulin receptor substrate protein inhibitors; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Colorectal cancer; Solid tumours; Squamous cell cancer
  • Preclinical Malignant melanoma

Most Recent Events

  • 18 Jun 2025 Purple Biotech in collaboration with University of Colorado initiates a phase I/II trial for Squamous cell carcinoma (Recurrent, Metastatic disease, Second line therapy or greater, Combination therapy) (NCT06919666)
  • 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Squamous cell carcinoma presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 09 Apr 2025 University of Colorado plans a phase I/II trial for Squamous cell carcinoma (Recurrent, Metastatic disease, Second line therapy or greater, Combination therapy) in June 2025 (NCT06919666)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top